Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Designing CeTiO<sub>x</sub>-based composite encapsulation overlayer on platinum for enhanced methanol steam reforming.

Journal of colloid and interface science·2026
Same author

The metabolic change trajectory of skeletal muscle during the life cycle: arteriovenous metabolomics.

Life medicine·2026
Same author

Covalent Ligand-AChE Adduct is a Bidirectional Indicator for Either Ligand or AChE: Pesticides as the Case.

Analytical chemistry·2026
Same author

Analysis of <i>Fusarium graminearum</i> Species Complex in Wheat-Maize and Wheat-Rice Rotation Fields in Henan, China.

Phytopathology·2026
Same author

Early prediction model for in-hospital all-cause death in patients with acute ST-elevation myocardial infarction after primary coronary artery stenting.

Frontiers in cardiovascular medicine·2026
Same author

Controllability Determines the Incentive Effect of Reward and Punishment: EEG Evidence.

Psychophysiology·2026
Same journal

BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance.

Current hematologic malignancy reports·2026
Same journal

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

Current hematologic malignancy reports·2026
Same journal

Germline DDX41 Variants: Current Understanding and Future Directions.

Current hematologic malignancy reports·2026
Same journal

Clonal Signatures of Telomere Biology Disorders.

Current hematologic malignancy reports·2026
Same journal

Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.

Current hematologic malignancy reports·2026
Same journal

The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes.

Current hematologic malignancy reports·2026
See all related articles

Related Experiment Video

Updated: Apr 13, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

Next-generation sequencing-based panel testing for myeloid neoplasms.

Frank C Kuo1, Fei Dong

  • 1Center for Advanced Molecular Diagnostics, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA, fkuo@partners.org.

Current Hematologic Malignancy Reports
|May 3, 2015
PubMed
Summary
This summary is machine-generated.

Next-generation sequencing (NGS) panels enhance the diagnosis of myeloid neoplasms by identifying genetic alterations. These tests offer valuable prognostic and therapeutic information, improving patient management.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.4K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K

Related Experiment Videos

Last Updated: Apr 13, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.4K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K

Area of Science:

  • Hematology
  • Genetics
  • Molecular Diagnostics

Background:

  • Next-generation sequencing (NGS) has revolutionized the identification of genetic alterations in myeloid neoplasms.
  • Traditional diagnostic methods like morphology, flow cytometry, and cytogenetics are complemented by NGS-based testing.
  • Numerous myeloid-focused NGS panels are now commercially and academically available.

Purpose of the Study:

  • To review the content of currently available myeloid-focused NGS panels.
  • To contextualize panel content within the understanding of driver alterations in myeloid neoplasms.
  • To assess the role of NGS panel testing in the future management of myeloid neoplasms.

Main Methods:

  • Review of existing literature and commercial/academic NGS panels for myeloid neoplasms.
  • Analysis of panel content in relation to known driver genetic alterations.
  • Evaluation of the impact of NGS on diagnostic workup, turnaround time, cost, and clinical significance.

Main Results:

  • NGS panels interrogate a wide spectrum of genetic alterations in myeloid neoplasms.
  • These panels provide additional diagnostic information beyond conventional methods.
  • The number of available myeloid-focused NGS panels has significantly increased.

Conclusions:

  • NGS-based panel testing is increasingly integral to the diagnostic workup of myeloid neoplasms.
  • Improved turnaround times, reduced costs, and growing knowledge of variant significance support the role of NGS.
  • NGS panel testing is poised to become a major tool in managing patients with myeloid neoplasms over the next decade.